Kyle Munz

The poster session at the Americas Committee for Research and Treatment in Multiple Sclerosis (ACTRIMS) Forum 2024 dedicated a section to emerging developments in the use of artificial intelligence (AI) in research and treatment approaches in multiple sclerosis (MS).

Speakers on the final day of the Americas Committee for Research and Treatment in Multiple Sclerosis (ACTRIMS) Forum 2024 discussed advancements in rehabilitation trials in multiple sclerosis (MS) and unmet research needs.

On day 2 of the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum 2024, speakers gave great attention to novel developments in the field of imaging and 3D modeling in multiple sclerosis (MS).

Young investigators spoke to emerging metabolic and cognitive research in multiple sclerosis (MS) at the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum 2024.

Speakers at the Americas Committee for Treatment and Research in Multiple Sclerosis Forum 2024 focused their attention on avenues to improve research accessibility for investigators and care access for patients with multiple sclerosis (MS).

The Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum 2024 opened with discussions on the novel concepts emerging in multiple sclerosis (MS) research, such as the associations between synaptic loss and hypoxia with disease progression.

Advocates for health insurance reform indicate the need to make system-wide, policy-level changes to improve patient outcomes, which include investing in improved access to care and lowering the burden of administrative costs.

An ecological study revealed increasing rates of skin cancer overdiagnosis in white Americans.

A cross-sectional study analyzing morphological and dimensional features of palatal rugae patters revealed that distinct anomalies exist in children with sickle cell disease (SCD) compared with children without.

The Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) will host its ninth annual meeting in West Palm Beach, Florida, from February 29 to March 2, 2024, to address a plethora of barriers faced by patients and clinicians managing multiple sclerosis (MS).

Patrick Vermersch, MD, PhD, joined The American Journal of Managed Care® for an interview on promising data from a phase 2 clinical trial on frexalimab in the treatment of multiple sclerosis (MS) and associated neurodegeneration.

A meta-analysis on complement inhibitors in the management of paroxysmal nocturnal hemoglobinuria (PNH) reveals an association between these interventions and positive treatment outcomes.

Andrew Ress, MD, discusses the novel integration of artificial intelligence (AI) into the skin cancer treatment landscape.

A bidirectional Mendelian randomization (MR) study found a casual relationship between sleep-related phenotypes (SRPs) and gut microbiota.

A meta-analysis of 3 case-controlled MS studies showed an association between susceptibility to multiple sclerosis (MS) and the vitamin D pathway.

Pain screening in young patients with sickle cell disease (SCD) has demonstrated benefits for the administration of integrative health and medicine modalities for pain management.

Business and practice updates from our Strategic Alliance Partners.

Researchers found significant associations between individual patterns and preferences for sleeping and their biological, phenotypical age.

A single-institution, retrospective cohort study evaluates knowledge gaps in clinical data on Black patients with melanoma.

A national single-center observational retrospective study reveals the long-term benefits of hematopoietic stem cell transplantation in the treatment of multiple sclerosis (MS).

A cross-sectional comparative study demonstrated the increased prevalence of hearing impairment in children and adults with sickle cell disease (SCD) or sickle cell traits compared with healthy individuals.

A longitudinal, observational study found that the choroid plexus, a network of blood vessels in each ventricle of the brain, plays a potential role in the neurodegenerative and chronic inflammatory process experienced by patients with relapsing remitting multiple sclerosis (MS).

A global analysis of sleep duration and irregularity gathered data on the adult population’s sleep patterns.

A case-control study found that patients with early-onset Merkel cell carcinoma exhibited genetic variations associated with the development of their disease.

OneOncology and the South Carolina-based Coastal Cancer Center recently announced the acquisition of 2 community-based radiation oncology centers.

A survey revealed the influence of prior stigmatic or discriminatory experiences on sexual and gender minority (SGM) patients’ perceptions of screening for skin cancer, stressing the need for affirming clinical settings.

The use of ibudilast in the treatment of progressive multiple sclerosis (MS) has been suggested to reduce lesion volume in patients.

A state-wide analysis draws attention to the fact individuals with sickle cell disease (SCD) completed a vaccination against COVID-19 at nearly half the rate of individuals without SCD.

A retrospective analysis surveys the treatment landscape and patterns of patients with paroxysmal nocturnal hemoglobinuria (PNH), illuminating high hospitalization rates and emergency department use despite the availability of multiple treatment options.

A systematic review of randomized controlled trials and prospective cohort studies concludes that sleep could be a prognostic component of lower back pain, but better evidence is needed.